CCCC
Price:
$5.4
Market Cap:
$374.42M
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X muta...[Read more]
Industry
Biotechnology
IPO Date
2020-10-02
Stock Exchange
NASDAQ
Ticker
CCCC
According to C4 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 369.73M. This represents a change of 23.25% compared to the average of 299.97M of the last 4 quarters.
The mean historical Enterprise Value of C4 Therapeutics, Inc. over the last ten years is 776.93M. The current 369.73M Enterprise Value has changed 4.66% with respect to the historical average. Over the past ten years (40 quarters), CCCC's Enterprise Value was at its highest in in the September 2021 quarter at 2.03B. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.
Average
776.93M
Median
687.01M
Minimum
224.85M
Maximum
1.45B
Discovering the peaks and valleys of C4 Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 186.92%
Maximum Annual Enterprise Value = 1.45B
Minimum Annual Increase = -76.15%
Minimum Annual Enterprise Value = 224.85M
Year | Enterprise Value | Change |
---|---|---|
2023 | 224.85M | -34.95% |
2022 | 345.68M | -76.15% |
2021 | 1.45B | 14.32% |
2020 | 1.27B | 24.43% |
2019 | 1.02B | 186.92% |
The current Enterprise Value of C4 Therapeutics, Inc. (CCCC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
673.28M
5-year avg
861.30M
10-year avg
776.93M
C4 Therapeutics, Inc.’s Enterprise Value is greater than Shattuck Labs, Inc. (110.17M), greater than Eliem Therapeutics, Inc. (272.53M), greater than Prelude Therapeutics Incorporated (257.24M), greater than Monte Rosa Therapeutics, Inc. (284.72M), greater than Foghorn Therapeutics Inc. (318.59M), greater than Cyteir Therapeutics, Inc. (-20511738.00), greater than Rezolute, Inc. (237.24M), greater than Century Therapeutics, Inc. (138.60M), less than Edgewise Therapeutics, Inc. (1.60B), less than Mineralys Therapeutics, Inc. (490.57M), less than Cullinan Oncology, Inc. (930.13M), less than Arvinas, Inc. (1.52B), less than Nurix Therapeutics, Inc. (1.41B), less than Kymera Therapeutics, Inc. (2.92B), less than Revolution Medicines, Inc. (6.80B),
Company | Enterprise Value | Market cap |
---|---|---|
110.17M | $167.05M | |
272.53M | $495.57M | |
257.24M | $266.87M | |
284.72M | $349.21M | |
318.59M | $416.63M | |
-20511738.00 | $108.71M | |
237.24M | $240.80M | |
138.60M | $123.69M | |
1.60B | $1.64B | |
490.57M | $558.43M | |
930.13M | $1.04B | |
1.52B | $1.68B | |
1.41B | $1.50B | |
2.92B | $2.89B | |
6.80B | $6.99B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like C4 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like C4 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is C4 Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for C4 Therapeutics, Inc. (CCCC)?
What is the 3-year average Enterprise Value for C4 Therapeutics, Inc. (CCCC)?
What is the 5-year average Enterprise Value for C4 Therapeutics, Inc. (CCCC)?
How does the current Enterprise Value for C4 Therapeutics, Inc. (CCCC) compare to its historical average?